Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington’s Cancer Research Endowment

Grants totaling approximately $3.5 million will support Deverra’s CAR-NK and engineered myeloid cell programs in hematologic malignancies and solid tumors WEXFORD, Pa., Sept. 11, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a…